DMX-200 (repagermanium), another CCR2 inhibitor, designed to inhibit recruitment of monocytes implicated in inflammatory chemokine environment, is currently investigated in patients with FSGS and concomitant RAS inhibition therapy (NCT05183646). Here, CCR2 is linked to focal segmental glomerulosclerosis.